These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34055190)

  • 21. Novel Tretinoin 0.05% Lotion for the Once-daily Treatment of Moderate-to-Severe Acne Vulgaris in an Adult and Adolescent Female Population.
    Kircik LH; Baldwin H; Lain E; Guenin E; Harris S; Bhatt V
    J Drugs Dermatol; 2019 Feb; 18(2):178-188. PubMed ID: 30811141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in an Asian Population.
    Han G; Armstrong AW; Desai SR; Guenin E
    J Drugs Dermatol; 2019 Sep; 18(9):910-916. PubMed ID: 31524347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Tretinoin 0.05% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in a Hispanic Population.
    Cook-Bolden FE; Weinkle SH; Guenin E; Bhatt V
    J Drugs Dermatol; 2019 Jan; 18(1):32-38. PubMed ID: 30681791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
    Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
    J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.
    Stein Gold L; Elewski B; Draelos Z; Jacobson A; Lin T
    J Drugs Dermatol; 2020 May; 19(5):504-514. PubMed ID: 32484629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
    J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies.
    Draelos ZD
    J Dermatolog Treat; 2023 Dec; 34(1):2166346. PubMed ID: 36622889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream.
    Draelos Z; Tanghetti E; Werschler W; Kircik L; Angel A; Lagmay E; Guenin E
    J Drugs Dermatol; 2022 Mar; 21(3):250-257. PubMed ID: 35254756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris.
    Tyring SK; Kircik L; Pariser DM; Woolery-Lloyd HC; Harper JC; Bhatt V; Pillai R; Guenin E
    Am J Clin Dermatol; 2020 Dec; 21(6):891-899. PubMed ID: 32886337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac
    Sidgiddi S; Allenby K; Okumu F; Gautam A
    J Clin Aesthet Dermatol; 2019 Sep; 12(9):16-24. PubMed ID: 31641413
    [No Abstract]   [Full Text] [Related]  

  • 31. Development of a Tape-Stripping Liquid Chromatography-Mass Spectrometry Method for Evaluating Skin Deposition of Topical Tazarotene.
    Draelos ZD; Draelos MM
    J Drugs Dermatol; 2021 Oct; 20(10):1105-1111. PubMed ID: 34636513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 Years and Older.
    Tyring SK; Kircik LH; Pariser DM; Guenin E; Bhatt V; Pillai R
    J Drugs Dermatol; 2018 Oct; 17(10):1084-1091. PubMed ID: 30365589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris.
    Pariser D; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2008 Jun; 7(6 Suppl):s18-23. PubMed ID: 18575222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.
    Bhatia ND; Pariser DM; Kircik L; Lin T; Harris S; Mathew L; Pillai R
    J Clin Aesthet Dermatol; 2018 Nov; 11(11):15-19. PubMed ID: 30588269
    [No Abstract]   [Full Text] [Related]  

  • 36. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies.
    Feldman SR; Werner CP; Alió Saenz AB
    J Drugs Dermatol; 2013 Apr; 12(4):438-46. PubMed ID: 23652892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris.
    Tanghetti E; Dhawan S; Torok H; Kircik L
    Dermatol Online J; 2007 Jul; 13(3):1. PubMed ID: 18328195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population.
    Eichenfield LF; Sugarman JL; Guenin E; Harris S; Bhatt V
    Pediatr Dermatol; 2019 Mar; 36(2):193-199. PubMed ID: 30656753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment.
    Leyden JJ; Shalita A; Thiboutot D; Washenik K; Webster G
    Clin Ther; 2005 Feb; 27(2):216-24. PubMed ID: 15811485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis.
    Shergill M; Ali MU; Abu-Hilal M
    Dermatol Ther (Heidelb); 2024 May; 14(5):1093-1102. PubMed ID: 38733511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.